The HIV protease inhibitor nelfinavir inhibits Kaposi's sarcoma-associated herpesvirus replication in vitro
about
Recent advances in understanding Kaposi's sarcoma-associated herpesvirusKSHV reactivation and novel implications of protein isomerization on lytic switch controlHistone deacetylase classes I and II regulate Kaposi's sarcoma-associated herpesvirus reactivation.Nelfinavir inhibits maturation and export of herpes simplex virus 1.Reduced human herpesvirus-8 oropharyngeal shedding associated with protease inhibitor-based antiretroviral therapy.Insights into the broad cellular effects of nelfinavir and the HIV protease inhibitors supporting their role in cancer treatment and preventionNew cell-signaling pathways for controlling cytomegalovirus replication.Nelfinavir impairs glycosylation of herpes simplex virus 1 envelope proteins and blocks virus maturationEffect of cytomegalovirus co-infection on normalization of selected T-cell subsets in children with perinatally acquired HIV infection treated with combination antiretroviral therapy.Restricted Kaposi's sarcoma (KS) herpesvirus transcription in KS lesions from patients on successful antiretroviral therapyTreatment of Kaposi sarcoma-associated herpesvirus-associated cancers.A randomized controlled trial of highly active antiretroviral therapy versus highly active antiretroviral therapy and chemotherapy in therapy-naive patients with HIV-associated Kaposi sarcoma in South AfricaTreatment with valacyclovir, famciclovir, or antiretrovirals reduces human herpesvirus-8 replication in HIV-1 seropositive men.Cancer prevention in HIV-infected populations.Risk of congenital cytomegalovirus infection among HIV-exposed uninfected infants is not decreased by maternal nelfinavir use during pregnancy.The immunologic basis for severe neonatal herpes disease and potential strategies for therapeutic intervention.Brief Report: A Phase 1b/Pharmacokinetic Trial of PTC299, a Novel PostTranscriptional VEGF Inhibitor, for AIDS-Related Kaposi's Sarcoma: AIDS Malignancy Consortium Trial 059.Is nelfinavir exposure associated with cancer incidence in HIV-positive individuals?Screening of FDA-Approved Drugs for Inhibitors against Japanese Encephalitis Virus Infection.Anti-herpesvirus agents: a patent and literature review (2003 to present).KSHV targeted therapy: an update on inhibitors of viral lytic replication.An easily transfectable cell line that produces an infectious reporter virus for routine and robust quantitation of Kaposi's sarcoma-associated herpesvirus reactivation.HIV-protease inhibitors for the treatment of cancer: Repositioning HIV protease inhibitors while developing more potent NO-hybridized derivatives?The cellular peptidyl-prolyl cis/trans isomerase Pin1 regulates reactivation of Kaposi's sarcoma-associated herpesvirus from latencyDiagnosis and Treatment of Kaposi Sarcoma.Effects of Antiretroviral Therapy on Kaposi's Sarcoma-Associated Herpesvirus (KSHV) Transmission Among HIV-Infected Zambian Children.Rapid regression of Kaposi's sarcoma of the hard palate under therapy with boosted elvitegravir-containing fixdose antiretroviral combination therapy.Evolving Paradigms in HIV Malignancies: Review of Ongoing Clinical Trials
P2860
Q26751238-14A389F4-C515-4672-9108-66F3B80C4DA5Q28080937-25A46638-0AB4-4E71-8298-639F6AACFEBDQ30570559-2D970E2B-88AA-44FB-90A6-B16A41B90296Q33602791-9D703C0F-EE63-4C93-9D50-50EAB6C48D31Q33610926-C6D1107E-EAD1-4F3E-909D-32EBBD6B2D8BQ33642284-CC99AA07-E6EB-48C8-AF38-49F0727B70F1Q34793671-0575ED82-A101-4258-ADFA-5569055C8005Q35077455-711903EB-5C92-49F2-A9D7-F56DE531A85CQ35203449-4FF84B2A-409A-4919-B41D-C3C135F7874DQ35458156-E01310EE-4E89-4FEF-90BC-0D19E8D91710Q35895560-1F73C871-F425-4FEE-97DF-EB3A830C1036Q35989731-C47090C0-49CE-48A5-AF24-E746EF2FDBEFQ36301349-7314434A-F518-4C51-A3F0-D79C84DC1F47Q36680086-D4C2094D-858E-4846-9C6C-068B3B3B8C49Q36757599-995424AB-ED48-40CD-9DF5-6FB8411BF224Q36765590-4B651F07-19BD-43E9-9514-7BA66BB1ADDDQ36818306-80328EF0-7826-41EE-8C0C-CE473078BBFBQ36957884-DD6A09C7-F43B-418E-87B0-C0B2DD98EE19Q38156719-033B97B8-3491-4B80-8AAA-71BF30CC88D2Q38228015-40629023-75ED-498B-8472-2E2E46B276DAQ38271135-EBA9DFAE-11CB-42B7-A892-79DC276EBB62Q38700640-EC3AFABA-3E04-4389-9B90-28999816C041Q39015233-9AE9D587-B13B-4A59-82D4-4D4970155E4CQ39068717-F244B64D-6E1C-4E49-B8E5-8EDF1D350679Q39190555-81C2C4C3-FD6E-4687-810D-B15C16EDC38AQ40725718-7146187F-5AA6-4543-905E-7EE586A82EE7Q41254170-1C402D18-F438-4B28-B2F3-F576CB994DB6Q57172787-EDF0BBAA-D038-4D7D-99C6-8C040F1CF665
P2860
The HIV protease inhibitor nelfinavir inhibits Kaposi's sarcoma-associated herpesvirus replication in vitro
description
2011 nî lūn-bûn
@nan
2011 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի մարտին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
The HIV protease inhibitor nel ...... rpesvirus replication in vitro
@ast
The HIV protease inhibitor nel ...... rpesvirus replication in vitro
@en
type
label
The HIV protease inhibitor nel ...... rpesvirus replication in vitro
@ast
The HIV protease inhibitor nel ...... rpesvirus replication in vitro
@en
prefLabel
The HIV protease inhibitor nel ...... rpesvirus replication in vitro
@ast
The HIV protease inhibitor nel ...... rpesvirus replication in vitro
@en
P2093
P2860
P356
P1476
The HIV protease inhibitor nel ...... rpesvirus replication in vitro
@en
P2093
Adam P Geballe
Corey Casper
Eliora Gachelet
Jacquelyn Carlsson
Jeffrey Vieira
Matthew Gray
Michael Lagunoff
Minako Ikoma
P2860
P304
P356
10.1128/AAC.01295-10
P407
P577
2011-03-14T00:00:00Z